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Transcatheter Closure of Perimembranous Ventricular Septal Defects: Occluder
Waist Length and Post-Procedural Arrhythmias
Hong Wu1, Yong Zhou2, Xianxian Zhao3, Ni Zhu2, Feng Chen2, Bili Zhang4,
Xing Zhen2, Zhifu Guo2, Jianqiang Hu2, Yongwen Qin2
1Changhai Hospital, Shanghai, China, 2Changhai Hospital, Shanghai, China,
3Changhai Hospital, shanghai, China, 4Changhai Hospital, Shanghai,China
Background: complete atrioventricular block (cAVB) is considered as the most
serious post-procedural adverse event in transcatheter closure of perimembranous
ventricular septal defect (VSD). In our study, incidence of post-procedural arrhyth-
mias and its relationship with occluder waist-length were evaluated.
Methods: In this retrospective study, clinical data from perimembranous VSD
patients who had been treated with transcatheter occluders in our center from
December 2001 to December 2010 were analyzed. Patients were treated in two
groups, short-waist vs long-waist group. Patients were required for routine clinical
visit at 1, 3, 6, and 12 months after the procedure and once a year thereafter.
Results: 234 patients had been deployed with short-waist occluders (2.0 mmw2.5
mm) and 571 with long-waist occluders (3.5 mm-4.5 mm). The occlusion rate was
98.7% in patients occluded with the short-waist devices and 97.9% in patients
occluded with long-waist devices respectively. Patients treated with long-waist
occluders had signiﬁcantly less arrhythmias vs short-waist group (P<0.001). Partic-
ularly, 9 (3.8%) patients in the short-waist group had complete atrioventricular block
(cAVB) and 3 (1.3%) required permanent pacemaker implantation. In the long-waist
group, 4 (0.7%) patients had cAVB and 1 (0.2%) had permanent pacemaker place-
ment. The difference was statistically signiﬁcant (P<0.001). In addition, cAVB
occurrence was signiﬁcantly correlated with occluder waist-length. No signiﬁcant
differences were noted in other procedure-related complications between patients with
short-wasit devices and patients with long-waist devices.
Conclusions: In perimembranous VSD patients who underwent transcatheter occlu-
sion, occluder waist length received might be related to post-procedural cAVB.
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Efﬁcacy and Safety of Left Atrial Appendage Occlusion with the Watchman
Device without Post-Procedure Oral Anticoagulation.
Roberto Spina1, Paul Roy1, David Baron1, David W. Muller2, Brendan Gunalingam1
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Background: Left atrial appendage occlusion (LAAO) with the Watchman device
requires oral anticoagulation and antiplatelet therapy for 45 days post-procedure, to
allow for device endothelialization. We are the second group worldwide to report
ﬁndings on the safety and efﬁcacy of LAAO without oral anticoagulation (OAC) post-
procedure.
Methods: Multi-centre, prospective, non-randomized study of LAAO with the
Watchman device. Follow-up consisted of transesophageal echocardiography at 45
days, and visits at 3 monthly regular intervals thereafter. Approval for the procedure
was obtained at our cardiology/cardiothoracic surgery meeting.
Results: 43 patients underwent the Watchman procedure in the period February 2010
to May 2013. The mean age was 72 years, and 62% of the patients were male. The
median CHA2DS2VASc was 4. Out of 36 successful occlusions, 23 (64 %) were
treated with dual antiplatelet therapy (DAPT) post-procedure, two patients (6%) had
a single antiplatelet agent, and one (3%) had no anticoagulation at all. The remaining 9
(25%) were treated with OAC and anti-platelet therapy. Compared with the OAC
group, patients in the DAPT group had a marginally higher mean CHA2DS2VASc
score (3.6 versus 3.5), had a lower rate of previous thromboembolism (37.5% versus
50%), and a shorter mean follow-up (16 months versus 21 months). We prospectively
followed patients for an average of 17 months (range, 0-44 months). During follow-
up, no ischemic strokes occurred. By contrast, the expected annual ischemic stroke
rate in our cohort is 4%, and the observed rates in the Watchman and warfarin arms of
the PROTECT-AF trial were 1.4% and 2.2%, respectively, despite the former patient
cohorts having lower mean CHA2DS2VASc score (2.2). One patient in the DAPT
group suffered a fatal intracranial hemorrhage 6 weeks post procedure. One patient
died as a result of LAA perforation. 4/43 (9%) patients developed a pericardial
effusion requiring drainage. No device embolization or other serious complications
occurred.
Conclusions: Our experience suggests that in high-risk patients with serious contra-
indications to OAC, Watchman device deployment without OAC cover may be
feasible without increasing the risk of ischemic stroke.B206 JACC Vol 62/18/Suppl B j October 27–November 1,TCT-674
WATCHMAN Left Atrial Appendage Occluder In Octogenarians: Short-term
And One-year Follow-up
Sameer Gafoor1, Jennifer Franke1, Stefan C. Bertog1, Patrick Boehm1,
Maik Gonzaga1, Janine Bauer1, Annkathrin Braut1, Simon C. C. Lam1,
Laura Vaskelyte1, Ilona Hofmann1, Horst Sievert1
1CardioVascular Center Frankfurt, Frankfurt, Germany
Background: Left atrial appendage (LAA) occlusion is useful in patients with atrial
ﬁbrillation to avoid long-term anticoagulation. The safety and efﬁcacy in older
patients over 80 years of age is not well known.
Methods: A retrospective review of patients 80 years or older with atrial ﬁbrillation
who underwent LAA occlusion with the WATCHMAN device at our hospital was
performed. Baseline demographic, procedural, and follow-up data were obtained.
Results: Between June 2006 and June 2011, 26 patients (53.8% male, age 83 +/-2.6
years) were identiﬁed. Hypertension, coronary artery disease, and congestive heart
failure were present in 100%, 50%, and 38.4% respectively. Atrial ﬁbrillation was
permanent in 61.5% of patients, with 11.5% and 18.5% having a prior stroke or TIA,
respectively. Mean CHADS2 and CHADS-VASc scores were 3.2 and 5.3. Anti-
coagulation with vitamin K antagonists was used in 50% of patients. Multiple
appendage lobes were present in 11.5%. Procedures were successful in 92.3% of
patients. The procedure was unsuccessful in two patients due to device instability and
difﬁculty with positioning. At six months, one device thrombus and one episode of
atrial tachycardia was reported. One-year follow-up revealed no deaths, one pace-
maker implantation, one peripheral vascular procedure, and one additional hospitali-
zation due to CHF. No strokes were reported in the follow-up period.
Conclusions: WATCHMAN LAA Occluder implantation is feasible and safe in
octogenarians. Efﬁciency in stroke prevention is supported by an absence of cere-
brovascular events.
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Comparison of 5 devices used to treat Patent Foramen Ovale (PFO)
Koichiro Matsumura1, Rubine Gevorgyan2, Jonathan Tobis3
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Geffen School of Medicine, UCLA, Los Angeles, United States
Background: Several devices have been used in the past decade for transcutaneous
PFO closure to prevent conditions associated with PFO. Selection of the appropriate
device is important to effectively close the PFO but the closure rate of different
devices are not well described. In this retrospective study, the degree of right-to-left
shunting was quantiﬁed following the placement of 5 different PFO closure devices.
Methods: From January 2001 to January 2013, 327 patients underwent trans-
cutaneous PFO closure in our hospital. 167 patients received transcranial Doppler
(TCD) studies at pre procedure and after 3 months and repeated every 3 months to
evaluate effective PFO closure.
Results: An effective closure occurred in 150 patients (90%) over all devices.
Comparison of device type revealed the highest effective closure rate was associated
with the Amplatzer ASO device (100%), followed by the Amplatzer Cribriform
(93%), Gore Helex (90%), Amplatzer PFO (86%), and CardioSEAL (86%) device.
The highest rate of residual shunting at the end of the 12-month period was observed
in patients who received the 30mm Gore Helex device which has a signiﬁcantly higher
rate of residual shunting compared with the 20mm and 25mm Helex devices
(p<0.0001, Figure 1).Conclusions: Transcutaneous PFO closure has a high success rate, with residual
shunting occurring in about 10% of cases. The 30 mm Helex non-self-centered device
should be avoided in patients with large size PFO defects as it provides insufﬁcient
closure of the PFO tunnel. We recommend an Amplatzer ASD occluder for PFO
diameters greater than 12 mm based on balloon sizing.2013 j TCT Abstracts/POSTER/Non-valvular Structural Heart Disease
